Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [31] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    Powles, T
    Shamash, J
    Berney, D
    Oliver, RTD
    BRITISH JOURNAL OF CANCER, 2003, 89 (06) : 1140 - 1141
  • [32] Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    T Powles
    J Shamash
    D Berney
    R T D Oliver
    British Journal of Cancer, 2003, 89 : 1140 - 1141
  • [33] PHASE-II STUDY OF IPROPLATIN (CHIP) IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS - THE NEED FOR ALTERNATIVE STRATEGIES IN THE INVESTIGATION OF NEW AGENTS IN GCT
    MURPHY, BA
    MOTZER, RJ
    BOSL, GJ
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) : 327 - 330
  • [34] Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update
    Koychev, D.
    Oechsle, K.
    Bokemeyer, C.
    Honecker, F.
    INTERNATIONAL JOURNAL OF ANDROLOGY, 2011, 34 (04): : E266 - E273
  • [35] Treatment of patients with cisplatin-refractory germ cell tumors [Behandlung von Patienten mit cisplatinrefraktären Keimzelltumoren]
    Koychev D.
    Honecker F.
    Bokemeyer C.
    Albers P.
    Der Onkologe, 2013, 19 (7): : 564 - 567
  • [36] Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
    Mego, M.
    Svetlovska, D.
    De Angelis, V
    Kalavska, K.
    Lesko, P.
    Makovnik, M.
    Obertova, J.
    Orszaghova, Z.
    Palacka, P.
    Reckova, M.
    Rejlekova, K.
    Sycova-Mila, Z.
    Mardiak, J.
    Chovanec, M.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1080 - 1086
  • [37] Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
    M Mego
    D Svetlovska
    De Angelis V
    K Kalavska
    P Lesko
    M Makovník
    J Obertova
    Z Orszaghova
    P Palacka
    M Rečková
    K Rejlekova
    Sycova-Mila Z
    J Mardiak
    M Chovanec
    Investigational New Drugs, 2022, 40 : 1080 - 1086
  • [38] Cisplatin-refractory germ cell tumors. Resistance mechanisms - therapy standards - new developments
    Oing, Christoph
    Seidel, Christoph
    Alsdorf, Winfried H.
    Bokemeyer, Carsten
    ONKOLOGE, 2017, 23 (02): : 123 - 128
  • [39] Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    C Bokemeyer
    British Journal of Cancer, 2003, 89 : 1141 - 1142
  • [40] Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    Kollmannsberger, C
    Bokemeyer, C
    BRITISH JOURNAL OF CANCER, 2003, 89 (06) : 1141 - 1142
12345